Related Experiment Video

Updated: Jul 30, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K

Reviewing the Prospective Pharmacological Potential of Isothiocyanates in Fight against Female-Specific Cancers

Shoaib Shoaib1, Farheen Badrealam Khan2, Meshari A Alsharif3

  • 1Department of Biochemistry, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh 202002, India.

Cancers
|May 16, 2023
PubMed

Insights

Isothiocyanates (ITCs) show promise in fighting female cancers by inhibiting growth and enhancing chemotherapy. Further research into ITCs

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Gynecological cancers represent a significant global health burden for females.
  • Current treatments face limitations, driving research into novel therapeutic strategies.
  • Alternative medicines, including natural compounds, are gaining attention for their potential efficacy and safety.

Purpose of the Study:

  • To review the molecular mechanisms of Isothiocyanates (ITCs) in female-specific cancers.
  • To explore the potential of ITCs as a standalone or combination therapy for these cancers.
  • To highlight advances in understanding ITCs for improved cancer treatment outcomes.

Main Methods:

  • Literature review focusing on Isothiocyanates (ITCs) and their role in gynecological malignancies.
  • Analysis of studies detailing ITC-mediated effects on cancer cell growth, apoptosis, epigenetics, autophagy, and cancer stem cells.
  • Examination of evidence regarding ITC-induced chemo-sensitization and combination therapies.

Main Results:

  • Isothiocyanates (ITCs), including sulforaphane, benzyl isothiocyanate, and phenethyl isothiocyanate, demonstrate potent anti-cancer activities.
  • ITCs inhibit cancer cell growth, induce apoptosis, alter epigenetic profiles, and modulate autophagy and cancer stem cells.
  • ITCs enhance the efficacy of conventional chemotherapeutic drugs, showing improved outcomes in combinatorial regimens.

Conclusions:

  • Isothiocyanates (ITCs) possess significant therapeutic potential for female-specific cancers.
  • Their ability to act as chemo-sensitizers suggests a valuable role in combination therapies.
  • Further understanding of ITC molecular intricacies may lead to novel treatment strategies and improved patient prognosis.
Keywords:
Isothiocyanatesbenzyl isothiocyanatebreast cancercervical cancerovarian cancerphenethyl isothiocyanatesulforaphane

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.2K

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.6K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
330
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K